In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HeartPort: Still Beating

Executive Summary

Once one of the highest-flying medical device companies of the 1990s, the last couple of years have not been easy for minimally-invasive cardiac surgery company, HeartPort Inc. The company developed an innovative approach to minimally-invasive bypass and heart valve surgery, one that incorporated the use of CPB (coronary-pulmonary bypass) in a closed procedure on the theory that CPB is the gold standard in open procedures. The problem is, no one wanted it. (Most surgeons would like to eliminate CPB from open procedures, if possible.) As adoption rates of its technology lagged far behind the company's projections, HeartPort became a fading star. But company officials insist HeartPort's fortunes are turning around.

You may also be interested in...



HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology

Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?

HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology

Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?

Cardica: Rebuilding the Cardiac Surgery Market

The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV001367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel